AIDS
Conditions
Interventions
Sponsors
Shanghai Public Health Clinical Center
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age >= 18 years old; 2.Confirmed HIV infection and initiation of ART for >= 6 month; 3.Not diagnosed with MetS at baseline; 4.Individuals who can understand and comply with the requirements of the research protocol and voluntarily sign a written informed consent form;
Exclusion criteria
Exclusion criteria: 1.Complicated with severe opportunistic infections (such as active tuberculosis, cryptococcal meningitis) or tumors; 2.Suffering from major neurological and psychiatric diseases such as schizophrenia, epilepsy, and severe depression/anxiety; 3.People with a history of drug abuse or a recent history of alcohol or drug dependence; 4.People with a history of allergies to any ingredient or excipient of the study drug, or those with a hypersensitive constitution. 5.Pregnant or lactating women; women of childbearing age who have not adopted contraceptive measures considered effective by the researcher (such as diaphragms, condoms, intrauterine devices, etc.; partner's vasectomy); 6.Individuals in the active phase of infectious diseases, the acute phase of severe cardiovascular diseases, or other conditions that the researcher deems unsuitable for participation in the study; 7.Baseline eGFR < 60 mL/min/1.73m^2 or a history of diabetes; 8.Individuals deemed unsuitable for participation in the study by the researcher for other reasons (such as contraindicated populations and unsuitable populations specified in the instruction manual, etc.);
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of metabolic syndrome (MetS) in HIV-infected individuals in different subgroups receiving various ART regimens, and changes in metabolism-related indicators (abdominal obesity, blood pressure, fasting blood glucose, TG, HDL-C); | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in metabolism-related indicators (abdominal obesity, blood pressure, fasting blood glucose, TG, HDL-C);The proportion of patients with HIV RNA <50 copies/ml, and the changes from baseline in CD4 T cells, CD8 T cells, and the CD4/CD8 ratio;Proportion of antiviral treatment failure, therapy regimen change, and patient adherence;Changes in liver and kidney function compared to baseline;Incidence of adverse events (AE); | — |
Countries
China
Contacts
Public ContactShen Yinzhong
Shanghai Public Health Clinical Center
Outcome results
None listed